ArticleCancer reports (Hoboken, N.J.)2025
Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High-Performance Silicon Nanowire Array Biosensor for Combined Detection of Colorectal Cancer Biomarkers.Micromachines · 2025Article
- Site-Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEarly prediction of metastatic risk after tumor resection for colorectal cancer (CRC) is critical to improve treatment outcomes. Although circulating tumor DNA (ctDNA) is an important biomarker in CRC patients, positivity is variable because cutoff values for each gene have not been clearly established. When examining the mutant allele frequency (MAF) of a gene, the cutoff value is the same for the same gene, even if the mutation sites are different. In this study, we examined the relationship between MAF and the genetic mutation site and factors that influence the prediction of recurrence by ctDNA.
methodsThis study included 422 CRC patients who underwent surgery. ctDNA was sampled from blood samples of 102 CRC patients with KRAS, NRAS, and BRAF mutations and analyzed using the digital polymerase chain reaction system. Preoperative, postoperative day 1, postoperative day 7, and postoperative day 30 MAF were examined for each gene mutation site.
resultsKruskal-Wallis test revealed significant differences in MAF between mutated codon sites at all MAF assessment times (p < 0.001). The MAF values of KRAS codon 146 at all time points were significantly higher than for the other mutation sites. Steel-Dwass tests revealed KRAS codon 146 had significantly higher MAF values than KRAS codons 12 and 13 on all blood collection dates. Similarly, BRAF codon 600 had significantly higher MAF values than KRAS codon 12 on all blood collection dates.
conclusionsThis study revealed that MAF values differed significantly depending on the site of mutation, even for the same gene. These results suggest that MAF cutoff values may need to be established for each gene mutation site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.